πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated β€” grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≀24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β€” use filters for patent-cliff planning.

Page 62 of 173

  1. US 10272184

    Hydrogel membrane for adhesion prevention

    Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10272037

    Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract

    Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10272055

    Therapeutic compounds and methods

    Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10273274

    Compositions and methods for inhibiting tumor cells by inhibiting the transcription factor ATF5

    Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10272084

    Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy

    Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10272099

    Tumor-selective combination therapy

    Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10272139

    Process, tube and device for the preparation of wound healant composition

    Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10272069

    Methods of treating muscular dystrophy

    Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10272093

    Use of H3K9me3 modulation for enhancing cognitive function

    Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10272034

    Auris formulations for treating otic diseases and conditions

    Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10267786

    Systems and methods for high-resolution imaging

    Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10265387

    Compositions and methods for treatment of homocystinuria

    Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10265405

    Polymers for delivery of factor VIII and/or factor IX

    Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10265439

    Injectable cell-laden biohybrid hydrogels for cardiac regeneration and related applications

    Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10266850

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10265372

    Molecular composition for enhancing and rejuvenating maintenance and repair of mammalian tissues

    Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10265394

    Compositions and methods for self-adjuvanting vaccines against microbes and tumors

    Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10265329

    Altering steroid metabolism for treatment of steroid-dependent disease

    Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10265338

    Compounds and methods for treating neurological and cardiovascular conditions

    Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10259781

    Imaging agents

    Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10259824

    Complement C3d-binding compounds

    Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10259846

    Bouvardin derivatives and therapeutic uses thereof

    Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10258606

    Endothelin single nucleotide polymorphisms and methods of predicting Ξ²-adrenergic receptor targeting agent efficacy

    Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10258613

    Compositions for treating retinal degeneration and methods of production and use thereof

    Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10258629

    Liposomal drug encapsulation

    Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10258631

    Formulations of testosterone and methods of treatment therewith

    Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10260101

    C-kit oncogene mutations in melanoma

    Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10258645

    Citrate containing beverage

    Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10259845

    Peptides whose uptake by cells is controllable

    Expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10253424

    Porous particles and methods of making thereof

    Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10253297

    Stem cell aggregates and methods for making and using

    Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10251909

    Potassium-magnesium citrate as a surrogate of the DASH diet in managing hypertension

    Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10251914

    Compositions and methods for transplantation of colon microbiota

    Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10251398

    Improving shelf life and color profile of resin compositions with silver nanoparticles

    Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10251923

    Therapeutic uses of mastic gum fractions

    Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10251955

    Heparin-mimicking sulfonated reverse thermal gel for the delivery of heparin-binding therapeutic proteins

    Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10253044

    9H-pyrimido [4,5-b]indoles and related analogs as BET bromodomain inhibitors

    Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10251778

    Therapeutics dispensing device and methods of making same

    Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10253039

    Inhibitors of bacterial DNA gyrase with efficacy against gram-negative bacteria

    Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10251977

    Compositions and methods for tissue repair with extracellular matrices

    Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10251894

    Anticonvulsant activity of steroids

    Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10253024

    Polycyclic indoline and indolenine compounds

    Expires Mon Apr 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10246471

    ETP derivatives

    Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10245330

    Compositions and methods for imaging

    Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10249389

    Individual and cohort pharmacological phenotype prediction platform

    Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10245322

    Nanostructured carriers for guided and targeted on-demand substance delivery

    Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10246464

    Thienopyrimidine and thienopyridine compounds and methods of use thereof

    Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10245255

    Compositions and methods for the treatment of obesity and related disorders

    Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.